NEW YORK, June 25, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and ...

In June 2022, Y-mAbs Therapeutics had US$134m in cash, and was debt-free. Looking at the last year, the company burnt through US$100m. So it had a cash runway of approximately 16 months from June ...

Y-mAbs Therapeutics YMAB announced that it has completed a pre-biologics license application (pre-BLA) meeting with the FDA for its B7-H3 inhibitor, omburtamab, to treat patients with CNS ...

PETACH TIKVA, Israel, Nov. 5, 2020 /PRNewswire/ -- Isotopia Molecular Imaging is pleased to announce that it has begun a collaboration with Y-mAbs Therapeutics, Inc., a late-stage clinical ...

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB), a commercial-stage biopharmaceutical company with a "GOOD" InvestingPro Financial ...

Y-mAbs Therapeutics, Inc. Q3 2022 DANYELZA® record product revenues of $12.5 million, YoY growth of 40% and 28% sequential increase compared to Q2 2022.

A high-level overview of Y-mAbs Therapeutics, Inc. (YMAB) stock. View (YMAB) real-time stock price, chart, news, analysis, analyst reviews and more.

Y-mAbs Therapeutics, Inc. Reported Total Revenues of $26.5 million for the fourth quarter of 2024 and $87.7 million for the full year 2024 . The Company established two business units in January ...